Bone Abstracts

The relationship between BMD T-score and FX risk has not been established in patients receiving osteoporosis therapy. In the FREEDOM Extension study, continuous DMAb therapy for up to 10 years increased BMD levels with no therapeutic plateau at lumbar spine or TH [Bone et al, ASBMR 2015]. Such improvements would only be meaningful if associated with FX reductions. We investigated the relationship between TH BMD T-score and NVFX in women who received DMAb during FREEDOM and tho...

Introduction: Parathyroid hormone (PTH) measurement is of use in i) differential diagnosis of hypercalcaemia and ii) patients with renal impairment at risk of bone disease. PTH immunoassays are complicated by cross-reactivity with truncated (inactive) variant forms, which accumulate in patients with renal impairment. PTH assay variability is a critical governance issue in renal medicine, suggesting an MS-based reference method is required.Aim: To develop...

Low circulating levels of total 25-hydroxyvitamin D (25OHD) have been reported in obese people of different ethnicities in several countries. Low total 25OHD in obesity could be due to lower binding proteins (with normal free 25OHD), lower dietary intake or sunlight exposure, greater volume of distribution (pool size) or more rapid metabolic clearance.The aims of this study were to determine if free 25OHD and 1,25-dihydroxyvitamin D (1,25(OH)2...

Abnormal tissue levels of certain trace elements such as Zinc (Zn) were reported in various types of cancer. Little is known about the role of Zn in osteosarcoma.Using confocal synchrotron radiation micro X-ray fluorescence analysis, we characterized the spatial distribution of Zn in high-grade (G3) sclerosing osteosarcoma of nine patients (4 f/5 m; 7 knee/1 humerus/1 femur) following chemotherapy and wide surgical resection. The study was done in accord...

Romosozumab is an investigational bone-forming agent that inhibits sclerostin. Recent data demonstrated that it stimulated bone formation, decreased bone resorption, and led to rapid and substantial increases in areal bone mineral density (BMD; McClung, J Bone Miner Res 27 (S1) S8–S9, 2012). In a Phase 1b, randomized, double-blind, placebo-controlled, multiple dose study, we studied the effects of romosozumab administered for 3 months and follow-...

see PP36....

see PP447....

Study aim: Vertebral strength is determined by bone size, shape, bone mineral density, microarchitecture, and bone material properties. Despite its importance to vertebral mechanics, no studies have reported on the variation of bone microdamage present in the human vertebra. Thus, the aim of this study was to assess regional changes in trabecular bone microdamage in association with bone microarchitecture and resorption in whole human lumbar vertebrae.Me...

Study aim: The general assumption that changes in bone microstructure and material properties at the iliac crest are representative of skeletal sites that are susceptible to osteoporotic fracture has not yet been addressed. Therefore, our study aim was to perform a comparative analysis of bone microarchitecture, accumulated microdamage and osteocyte morphology between the iliac crest, proximal femur and vertebral body.Methods: Trabecular bone cores were ...

Treatment with sclerostin antibody (Scl-Ab) increases bone formation and strength in animal models. Here, we aimed to i) characterize the longer-term effects of Scl-Ab on bone in cynomolgus monkeys (cynos) and ovariectomized (OVX) rats and ii) test whether follow-up treatment with OPG-Fc would maintain the bone mass gains induced by Scl-Ab in OVX rats. In the cynos study, 3 to 5-year-old male cynos were treated for 6 months with weekly SC injections of vehicle (Veh), 3, 10, or...